Preview

Пульмонология

Расширенный поиск

Ксолар (омализумаб): новые возможности терапии тяжелой бронхиальной астмы

https://doi.org/10.18093/0869-0189-2007-0-4-100-105

Полный текст:

Об авторе

Р. С. Фассахов
ФГУН "Казанский НИИ эпидемиологии и микробиологии Роспотребнадзора"
Россия
г. Казань


Список литературы

1. Pearce N., Pekkanen J., Beasley R. How much asthma is really attributable to atopy? Thorax 1999; 54: 268-272.

2. Novak N., Bieber T. Allergic and nonallergic forms of atopic diseases. J. Allergy Clin. Immunol. 2003; 112: 252–262.

3. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur. Respir. J. 2003; 22: 470–477

4. Haselkorn T., Borish L., Miller D.P. et al. High prevalence of skin test positivity in severe or difficult-to-treat asthma. J. Asthma 2006; 43: 745–752.

5. National Institutes of Health. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (Revised 2006). No. 02-3659. Bethesda, MD.

6. Barnes P.J. Should anti-inflammatory agents be used earlier in asthma? J. Respir. Dis. 1998; 19: S28–S34.

7. Barnes P.J. Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma. J. Allergy Clin. Immunol. 1998; 101: S427–S433.

8. Rabe K.F., Vermeire P.A., Soriano J.B., Maier W.C. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur. Respir. J. 2000; 16: 802–807.

9. Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am. J. Respir. Crit. Med. 2004, 170: 836–844.

10. Presta L., Shields R., O'Connell L. et al. The binding site on human immunoglobulin E for its high affinity receptor. J. Biol. Chem. 1994; 269: 26368–26373.

11. Maurer D., Ebner C., Reininger B. et al. The high affinity IgE receptor (FcεR1) mediates IgE-dependent allergen presentation. J. Immunol. 1995; 154: 6285–6290.

12. Reischl I., Corvaia N., Effenberger F. et al. 1996. Function and regulation of Fc?R1 expression on monocytes from non-atopic donors. Clin. Exp. Allergy. 26: 630–641.

13. Pirron U., Schlunk T., Prinz J., Rieber E. IgE dependent antigen focusing by human B lymphocytes is mediated by the low affinity receptor for IgE. Eur. J. Immunol. 1990; 20: 1547–1551.

14. Borish L.C., Nelson H.S., Lanz M.J., Claussen L. et al. Interleukin-4 receptor in moderate atopic asthma: a phase I/II randomized placebo-controlled trial. Am. J. Respir. Crit. Care Med. 1999; 160: 1816–1823.

15. Corne J., Djukanovic R., Thomas L. et al. The Effect of Intravenous Administration of a Chimeric Anti-IgE Antibody on Serum IgE Levels in Atopic Subjects: Efficacy, Safety, and Pharmacokinetics J. Clin. Invest. 1997; 99: 879–887.

16. Khazaeli M., Saleh M., Liu T. et al. Pharmakokinetics and immune response of 131 I-chimaeric mouse/human B72-3 (human gamma 4) monoclonal antibody in humans. Cancer. Res. 1991; 51: 5461–5466.

17. Hook W.A., Zinsser F.U., Berenstein E.H., Siraganian R.P. Monoclonal antibodies defining epitopes on human IgE. Mol. Immunol. 1991; 28: 631–639.

18. Presta L.G., Lahr S.J., Shields R.L. et al. Humanization of an antibody directed against IgE. J. Immunol. 1993; 151: 2623–2632.

19. Shields R.L., Whether W.R., Zioncheck K. et al. Inhibition of allergic reactions with antibodies to IgE. Int. Arch. Allergy Immunol. 1995; 107: 308–312.

20. Rudolf M.P., Zuercher A.W., Nechansky A. et al. Molecular basis for nonanaphylactogenicity of a monoclonal anti-IgE antibody. J. Immunol. 2000; 165: 813–819.

21. Fox J.A., Hotaling T.E., Struble C. et al. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 1996; 279 (2): 1000–1008.

22. Fahy J.V., Fleming H.E., Wong H.H. et al. The effect of an anti-IgE monoclonal antibody on the earlyand late-phase responses to allergen inhalation in asthmatic subjects. Am. J. Respir. Crit. Care Med. 1997; 155: 1828–1834.

23. MacGlashan D.W., Bochner B.S., Adelman C.D. et al. Down-regulation of Fc.RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J. Immunol. 1997; 158: 1438–1445.

24. Beck L.A., Marcotte G.V., MacGlashan D. et al. Omalizumab-induced reductions in mast cell Fc-epsilon RI expression and function. J. Allergy Clin. Immunol. 2004; 114 (3): 527–530.

25. Infuhr D., Crameri R., Lamers R., Achatz G. Molecular and cellular targets of anti-IgE antibodies. Allergy 2005; 60 (8): 977–985.

26. Chang T.W. The pharmacological basis of anti-IgE therapy. Nat. Biotechnol. 2000; 18: 157–162.

27. Prussin C., Griffith D.T., Boesel K.M. et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J. Allergy Clin. Immunol. 2003; 112: 1147–1154.

28. Holgate S.T., Djukanovic R., Casale T., Bousquet J. Antiimmunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin. Exp. Allergy 2005; 35 (4): 408–416.

29. Louis R., Lau L.C., Bron A.O. et al. The relationship between airways inflammation and asthma severity. Am. J. Respir. Crit. Care Med 2000, 161: 9–16.

30. Lim S., Jatakanon A., John M. et al. Effect of inhaled budesonide on lung function and airway inflammation: assessment by various inflammatory markers in mild asthma. Am. J. Respir. Crit. Care Med. 1999; 159: 22–30.

31. van Rensen E.L., Straathol K.C., Veselic!Charvat M.A. et al. Effect of inhaled steroids on airwai hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 1999; 54: 403–408.

32. Boulet L.!P., Chapman K.R., Cote J. et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am. J. Respir. Crit. Care Med. 1997; 155: 1835–1840.

33. Soler M., Matz J., Townley R. et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 2001; 18: 254–261.

34. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe asthma. J. Allergy Clin. Immunol. 2001; 108: 184–190.

35. Нolgate S.T., Chuchalin A., Herbert J. et al. Efficacy and safety a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy 2004; 34: 632–638.

36. Busse W.W. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am. J. Respir. Crit. Care. 2001; 164: S12–S17.

37. Noga O., Hanf G., Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int. Arch. Allergy Immunol. 2003; 131: 46–52.

38. Buhl R., Soler M., Matz J. et al. Omalizumab provides longterm control in patients with moderate-to-severe asthma. Eur. Respir. J. 2002; 20: 73–78.

39. Walker S., Monteil M., Phelan K. et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2003; 3: CD003559.

40. Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2004; 3: CD003559

41. Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2006. 19 (2): CD003559.

42. Bousquet J., Cabrera P., Berkman N. et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60 (3): 302-308.

43. Maykut R., Massanari M., Zeldin R. et al. In moderatesevere asthma, omalizumab reduced the need for rescue systemic steroid bursts and improved ratings of treatment effectiveness: a pooled analysis. J. Allergy Clin. Immunol. 2006; 117 (2): S10.

44. Ayres J.G., Higgins B., Chilvers E.R. et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59: 701–708.

45. National Institutes for Health, National Heart, Lung, and Blood Institute. Expert Panel Report 2. Guidelines for the diagnosis and management of asthma. NIH Publication no. 97–4051; 1997

46. Humbert M., Beasley R., Ayres J. et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309–316.

47. Bousquet J., Rabe K., Humbert M. et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir. Med. 2007; 101 (7): 1483–1482.

48. EU summary of product characteristics (SmPC) for omalizumab. Available at: www.emea.eu.int/humandocs/PDFs/EPAR/Xolair/H-606-PI-en.pdf


Для цитирования:


Фассахов Р.С. Ксолар (омализумаб): новые возможности терапии тяжелой бронхиальной астмы. Пульмонология. 2007;(4):100-105. https://doi.org/10.18093/0869-0189-2007-0-4-100-105

For citation:


Fassakhov R.S. Xolair (omalizumab): new opportunities of therapy of severe asthma. PULMONOLOGIYA. 2007;(4):100-105. (In Russ.) https://doi.org/10.18093/0869-0189-2007-0-4-100-105

Просмотров: 25


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)